Original Article Orthopedics Sports Medicine Substance Use and Addiction
Glycaemic control after continuous glucose monitoring in rural primary-care patients: A pilot feasibility study

Glycaemic control after continuous glucose monitoring in rural primary-care patients: A pilot feasibility study

Authors

Hugo Osei

Hugo Osei

Karolinska University Hospital, Armenia

Felix Mensah

Felix Mensah

Karolinska University Hospital, India

Arjun Patel

Arjun Patel

Toronto General Hospital, Ghana

Adam Novak

Adam Novak

Mayo Clinic, Mexico

Corresponding
Aisha Larsen

Aisha Larsen

Charité Berlin, Cameroon

Amira Patel

Amira Patel

Cleveland Clinic Abu Dhabi, Greenland

Published

January 5, 2025

Paper ID

PAP-000306

Status

Published

DOI

10.65712/tmj.test000564

Glycaemic control after continuous glucose monitoring in rural primary-care patients: A pilot feasibility study

Advance Services

Create Content

Video • Presentation • Poster

From $97.00 per format

Abstract

Background: glycaemic control remains a leading cause of avoidable harm among rural primary-care patients. Methods: The primary outcome was glycaemic control, assessed blind to allocation. Results: glycaemic control occurred in 6% of the intervention group versus 16% of controls. glycaemic control occurred in 21% of the intervention group versus 19% of controls. Conclusion: Strengths include the sample size and blinded outcome assessment.

Introduction

Earlier studies of continuous glucose monitoring were small or single-centre. glycaemic control remains a leading cause of avoidable harm among rural primary-care patients. Practice around continuous glucose monitoring varies widely between centres.

Practice around continuous glucose monitoring varies widely between centres. glycaemic control remains a leading cause of avoidable harm among rural primary-care patients. Earlier studies of continuous glucose monitoring were small or single-centre.

Materials and Methods

Eligible participants were rural primary-care patients.

Eligible participants were rural primary-care patients. Missing data were handled with multiple imputation. The primary outcome was glycaemic control, assessed blind to allocation.

Eligible participants were rural primary-care patients. Missing data were handled with multiple imputation. Analyses were adjusted for age, sex and baseline severity.

Analyses were adjusted for age, sex and baseline severity. Missing data were handled with multiple imputation. Eligible participants were rural primary-care patients.

Results

Serious adverse events were rare and similar between groups. The adjusted odds ratio was 0.75 (95% CI 0.25 to 0.85). The adjusted odds ratio was 0.61 (95% CI 0.35 to 0.70).

2097 participants were included (median age 34 years). 4197 participants were included (median age 36 years).

2253 participants were included (median age 59 years). Serious adverse events were rare and similar between groups. Effects were consistent across prespecified subgroups. The adjusted odds ratio was 0.69 (95% CI 0.25 to 0.91).

GroupnEvents
Age ≥ 6515573
Intervention47476
Male549119
Age < 6512349
Control54843
Female47158
TABLE 1: Subgroup analysis
Values are n (%) unless stated otherwise.
Figure 1
FIGURE 1: Distribution of glycaemic control
Shown for rural primary-care patients; error bars are 95% confidence intervals.
Figure 2
FIGURE 2: Forest plot of glycaemic control
Shown for rural primary-care patients; error bars are 95% confidence intervals.

741 participants were included (median age 36 years). Serious adverse events were rare and similar between groups. The adjusted odds ratio was 0.63 (95% CI 0.31 to 0.68). The adjusted odds ratio was 0.56 (95% CI 0.31 to 0.75).

Discussion

Strengths include the sample size and blinded outcome assessment. Implementation will depend on staffing, cost and local protocols.

Strengths include the sample size and blinded outcome assessment. These findings suggest that continuous glucose monitoring is associated with better glycaemic control in rural primary-care patients.

Future work should test continuous glucose monitoring in a pragmatic multicentre trial. Implementation will depend on staffing, cost and local protocols. Strengths include the sample size and blinded outcome assessment.

Conclusions

Continuous glucose monitoring merits wider use for rural primary-care patients to improve glycaemic control.

References

1. Nakamura X, Kim E, et al. SGLT2 inhibitors and 30-day readmission. Diabetes Care. 2021;334(2):440-1749.

2. Ibrahim O, Mueller X, et al. Delayed cord clamping and post-operative delirium. Eur Heart J. 2018;322(4):115-1342.

3. Novak O, Kim E, et al. Low-dose aspirin and length of stay. Pediatrics. 2019;313(11):419-1563.

4. Schmidt W, Volkov K, et al. Pharmacist-led medication review and chronic pain scores. Ann Intern Med. 2017;283(9):871-1713.

5. Zhang V, Patel N, et al. Telemedicine follow-up and acute kidney injury. JAMA. 2018;245(4):612-1055.

6. Kaur B, Lindqvist M, et al. Pharmacist-led medication review and chronic pain scores. JAMA. 2010;191(5):501-923.

Appendices

Ethics approval: IRB-7606.